Blocking P2X7 Receptor Cuts Brain Inflammation in Human Tissue — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Birmingham researchers led by Professor Nicholas Barnes found that blocking the P2X7 receptor significantly reduced inflammation in human brain tissue, with the study published in the journal Brain.
- The P2X7 receptor promotes the release of cytokines — inflammatory signaling proteins — and a specific antagonist against the receptor cut the inflammatory response in human tissue sharply.
- Professor Barnes said the discovery "marks a major step toward repurposing existing therapeutics" for Alzheimer's, Parkinson's, multiple sclerosis, traumatic brain injury, schizophrenia, and depression, all conditions where Barnes noted there are currently "no effective pharmacological treatments" to reduce neuroinflammation.
- The team developed a method to convert human peripheral monocytes (white blood cells) into microglia-like cells, addressing the long-standing problem that microglia lose their defining characteristics once removed from the brain.
- After identifying the response in the lab-grown microglia, researchers reproduced the same anti-inflammatory effect in human brain tissue obtained through neurosurgical procedures.
- Barnes said the next stage is developing clinical trials in patients with neurodegenerative conditions and traumatic brain injury, building on the existing P2X7-blocking drugs the team aims to repurpose.
Why it matters: The finding is unusually close to clinical translation: the anti-inflammatory effect was reproduced in real human brain tissue (not just cell lines or animal models), and the target — P2X7 — is already druggable with existing compounds, opening a repurposing path for conditions like Alzheimer's, Parkinson's, and TBI where no effective anti-inflammatory drugs currently exist.
Ask SkimNews
